drugset / Trial / NCT02811484
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
RandomizedFactorialDouble-blindTreatment
Summary
The purpose of this study is to see what the effects of using one or two additional diabetes drugs (dapagliflozin and exenatide-LAR) are on blood sugar levels in patients who are taking insulin. This research study is being done to investigate which of these commonly-used medications, medication combinations or increasing insulin dose is better.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-06
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped (Enrollment): “Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 5 mg | — |
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Subject | Exenatide LAR | Unknown | 2 mg | — |
| Background | Insulin Lispro | Protein / enzyme biologic | — | — |
| Background | insulin aspart | Protein / enzyme biologic | — | — |
| Background | insulin detemir | Protein / enzyme biologic | — | — |
| Background | insulin glargine | Protein / enzyme biologic | — | — |